companies / serifbio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-13 json
| total_raised | 50,000,00050.0M | ○ |
|---|---|---|
| founded | 2024 | |
| hq | Cambridge | |
| industry | unknown | |
| stage | seed |
Serif Biomedicines is a biotech developing therapeutics targeting underserved disease areas. It serves patients with severe diseases that lack effective therapies and the pharma partners that license its assets. The platform combines biology and computational discovery to identify novel drug targets.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-24 | seed | 50,000,00050.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Seed, $50.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |